

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY[®]

EDITORIAL

- Of Guides and Guidelines 329
WALTER J. HIERHOLZER, JR, MD

JOINT COMMISSION REPORT

- The Agenda for Change: Development of the Joint Commission Infection Control Indicators 331
KRISITNA L. KAZLAUSKAS, MHA; DEBORAH M. NADZAM, PHD, RN

ORIGINAL ARTICLES

- Human Immunodeficiency Virus Testing Experience and Hepatitis B Vaccination and Testing Status of Healthcare Workers in South Carolina: Implications for Compliance With US Public Health Service Guidelines 336
LUDWIG A. LETTAU, MD, MPH; DAWN W. BLACKHURST, MS; CONNIE STEED, RN, CIC

- Nosocomial Human Parvovirus B19 Infection: Lack of Transmission From a Chronically Infected Patient to Hospital Staff 343
DELORIS E. KOZIOL, PHD; GARY KURTZMAN, MD; JAMSHED AYUB, PHD; NEAL S. YOUNG, MD; DAVID K. HENDERSON, MD

- Impact of a Shielded Safety Syringe on Needlestick Injuries Among Healthcare Workers 349
BARBARA YOUNGER, RN, BSN, CIC, ELLA H. HUNT, RN; CECIL ROBINSON, RN; CHERYL MCLEMORE, RN

SHEA POSITION PAPER

- SHEA's Initiative for Confronting the Cost-Quality Conundrum 354
R. MICHAEL MASSANARI, MD, MS; BRYAN SIMMONS, MD;
THE SOCIETY FOR HOSPITAL EPIDEMIOLOGY OF AMERICA

CLINICAL PHARMACOLOGY OF ANTIBIOTICS

- Azithromycin and Clarithromycin: Overview and Comparison With Erythromycin 357
MARC S. WHITMAN, MD; ALLAN R. TUNKEL, MD, PHD

LETTERS TO THE EDITOR

- Pseudo-outbreak of Blastomycosis Associated With Contaminated Bronchoscopes 324
L.E. NICOLLE; J. MCLEOD; L. ROMANCE; S. PARKER; M. PARASKEVAS

- Heliport-associated Nosocomial Mucormycoses 325
MARK J. ABZUG, MD; SHERRY GARDNER, RN, BA; MARY P. GLODE, MD;
MARGRETE CYMANSKI, MS(ASCP); MARTHA ROE, MS(ASCP); LORRIE F. ODOM, MD

- SHEA NEWS 369

Introducing the benefits of catheter-related

ARROWgard™*. The first and only central venous catheter

Complications due to catheter-related bacteremia are medically unacceptable when the causes are preventable. And in today's health-care climate, the monetary cost of treating nosocomial infection versus the cost of prevention is similarly unacceptable.

Fortunately, the forces of prevention have gamed a new weapon. ARROWgard™ is a patented colo-

nization-resistant chlorhexidine and silver sulfadiazine antiseptic surface molecularly bonded into the polyurethane catheter material along the entire indwelling length of each ARROWgard™ blue line CVC.

A recent study indicates that catheters with ARROWgard™ protection were twofold less likely to be colonized than control catheters *and fourfold less likely to produce bacteremia*. The study also noted a considerable lengthening of the safe indwelling period for ARROWgard™ catheters compared to control catheters."

ARROWgard™ infection protection is presently available in select multi-lumen** and single-lumen CVC kits. It will soon be available on other Arrow critical-care products.

The benefits of CVCs are not without risk

There is no question that central venous catheterization (CVC) represents

a significant medical advancement, particularly in treatment of the critically ill. However, with increased usage there is an increased risk of CVC-related infection.

The reported frequency of intravascular device-associated bacteremia is between 0.2% and 0.5% for IV peripheral catheters, up to 7.0% for central parenteral nutrition catheters—and from **3.8% to 12.0% for central venous catheters**.² In short, 80% to 90% of each year's cases of intravascular-related bloodstream infection arise from the use of CVCs.³ Moreover, a 10% to 20% case fatality rate has been associated with catheter-related bacteremia?

In an address to

the Third International Conference on Nosocomial Infections,⁴ Dr. Dennis Maki stated that *one-third of nosocomial infections are preventable*, especially the 50,000 cases a year that develop from CVCs. Some 80% of these catheter-related infections arise from bacteria found on the skin that migrate down the catheter track, Dr. Maki noted.

Awareness is, of course, part of the battle. But more ammunition is needed. And that's why we developed ARROWgard™.

More infection control means more financial control

In a study published in 1988


reporting 1986 results, Hampton and Sheretz determined that nosocomial infection added a mean of seven days to a normal hospital stay and increased *the cost by a mean of more than \$6,000!*

⁵ An additional downside: Medicare reimburses very little of the cost if a hospital stay is extended to treat bacteremia.

When you add the increases in cost since these studies were made, the economic impact of CVC-related infection is even more severe. And while new drugs to fight septic infections offer hope of better management in some crisis cases, the extreme costs pose a *clinical dilemma for caregivers*.

But ARROWgard™ can help reverse those spiraling figures,

Let's say that a hospital places 500 multi-lumen CVCs a year. If the infection rate is 4%, 20 infections result. By




*4% Infection Rate and \$6,000 Mean Cost.^{3,5}

Clinical and Publication References: *Aoki, DG, Wheeler, SJ, Stolz, SM, Mermal, LA. Clinical trial of a novel antiseptic-coated central venous catheter. Abstract of paper presented at 31st ICAAC Clinical Infections, October 1, 1991. †Elliot, IS. Intravascular device infections. J. Med. Microbiol., 27: 161-167, 1988. ‡Gorins, MI, et al. Infections related to central venous catheters. Mayo Proc., 25: 979-985, 1990. §Maki, DG. Microbiol bloodstream infections. Address, 3rd Int. Conf. on Nosocomial Infections, Atlanta, July, 1990. ¶Hampton, AD, Sheretz, RJ. Vascular-access infections in hospitalized patients. Surg. Clin. North Am., 48: 57-71, February, 1988.

5 @ nining of the end ed bacteremia.

s catheters with built-in infection protection.

bringing the infection rate down to 2%, 10 cases would be avoided-and, at the figure of \$6,000 per case for added hospitalization, the added cost for infection would be cut in half, from \$120,000 to \$60,000. At a cost of \$68.20 per ARROWg^{ard}[™] multi-lumen CVC kit, or \$34,100 for 500 multi-lumen CVCs, the hospital retains over half the savings*



even after subtracting the catheter cost. Even more important than the economics, potentially, lives may be saved.² Further, you must consider the unnecessary expenditure of time and energy on the part of your staff and the trauma and suffering of the patient.

Additional patient and physician benefits.

Select Arrow multi-lumen and single-lumen central venous catheters now carry ARROWg^{ard}[™] protection. And there are other impressive benefits built into select ARROWg^{ard}[™] CVC kits and sets. These features add up to better patient care with every use.

- The Arrow Blue FlexTip[®] is an integral catheter tip which is more pliant than the body. It remains patent yet

deflects in case of inadvertent contact with the vessel walls to reduce perforation risk.

- Flexible thromboresistant polyurethane material softens in situ for excellent indwelling characteristics.
- The Arrow[®] Raulerson Introducer Syringe^{***}

has a hollow plunger with a patented valving system. It allows a spring-wire guide to be placed directly into the vessel lumen so there's less trauma, less contamination risk, and virtually no chance for air embolism.

- The Arrow Advancer[™] saves you time by helping you to easily straighten the "J"-tip spring-wire guide and insert it with one hand, advancing it to the proper position with your thumb.
- A centimeter-marked spring-wire

guide (.025" and .035" diameters available) aids in accurate and positive catheter placement.

MEDIAL 18GA

DISTAL 16G

PROXIMAL 14

Not only does Arrow offer more benefits, but you have a wider choice of kits, sets, and accessories for central venous catheterization from Arrow than from any other source.

Ask for our free infection-control information packet

We have prepared a helpful packet on infection control. It contains many of the articles referenced in this brochure and CVC informational literature. For your *free* packet, call your Arrow representative, or contact us directly by calling 1 800 233-3187, Ext. 3294, and ask for Joanne.

Refer to package insert for current warnings, precautions, and instructions for use.

* ARROWg^{ard}[™] is a joint development of Dexco Medical Sciences, Inc., and Arrow International, Inc., using technology developed by Dr. Shama Meek and colleagues, in the Department of Surgery, Columbia University, U.S. Patent Numbers 4,812,547; 4,822,445; 4,821,025; 5,115,056 apply. Other U.S. and foreign patents pending.


** U.S. Patent Number RE-31873; Canadian Patent Number 1,312,533; Foreign patents pending and issued. The Arrow-Hoess[™] Multi-Lumen Central Venous Catheter is a joint development of Randolph Hoess, M.D., Ph.D., and Arrow International, Inc.

*** U.S. Patent Number 4,281,328; Other U.S. and foreign patents pending. The Arrow Raulerson Syringe is a joint development of J. Daniel Raulerson, M.D. and Arrow International, Inc.

ARROW[™]

INTERNATIONAL, INC.

Contact our Customer Relations Department for further information: 3000 Berryville Road, Fliesing, PA 17035, U.S.A. Distribution worldwide; offices in Canada, Germany, Japan, The Netherlands, and France.



* Contact your Arrow representative for full details of this program.

Call for Nominations

Program

The programs will be held September 17-20 in Atlanta, Georgia, and November 19-22 in Salt Lake City, Utah. Donald A. Goldmann, MD, William Martone, MD, John P. Burke, MD, and Gina Pugliese, RN, MS, will co-chair the program. Enrollment in the programs is limited to 120.

Purpose

These programs, developed by the Society for Hospital Epidemiology of America (SHEA), the Centers for Disease Control (CDC), and the American Hospital Association (AHA), are intended for infectious disease fellows and new hospital epidemiologists. They emphasize hands-on exercises in which participants work in small groups to detect, investigate, and control epidemiological problems encountered in the hospital setting. These work sessions are supplemented with lectures and seminars covering fundamental aspects of hospital epidemiology including epidemiology and surveillance, epidemic investigation, transmission and control of nosocomial infections, disinfection and sterilization, employee health, isolation systems, regulatory compliance, and quality improvement.

Awards

Scholarships in the amount of \$1,000 will be awarded to five infectious disease fellows for each program to defray the special course fee for fellows of \$350 and expenses incurred in attending the training program.

Interested fellows must submit a letter of no more than one page describing why they would like to have additional training in hospital epidemiology. A letter from the fellow's program director outlining the applicant's qualifications and suitability for the course also is required. The letters should be received by **July 17, 1992**. Please **specify** the program dates (September 17-20, November 19-22, or both) for which you would like to be considered.

The SHEA Educational Activities Committee will select the scholarship recipients based on review of these letters. **Winners** will be notified in mid-August 1992 for both courses.

Nominations

Please send scholarship applications to:

Donald A. Goldmann, MD
Division of Infectious Diseases
Children's Hospital
300 Longwood Avenue
Boston, MA 02115

General Course Information

Information regarding the schedule, hotel and travel accommodations, discount airfare, and course fees are available from the AHA. Contact Brooke Baron at (312) 2804460. Note that application for a scholarship does not constitute enrollment in the program. This must be done separately.

Scholarship awards provided by



INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY™

CONTENTS

EDITORIAL

Of Guides and Guidelines **329**

WALTER J. HIERHOLZER, JR, MD

JOINT COMMISSION REPORT

The Agenda for Change: Development of the Joint Commission Infection Control Indicators **331**

KRISTINA L. KAZLAUSKAS, MHA, DEBORAH M. NADZAM, PHD, RN

ORIGINAL ARTICLES

Human Immunodeficiency Virus Testing Experience and Hepatitis B Vaccination and Testing Status of Healthcare Workers in South Carolina: Implications for Compliance With US Public Health Service Guidelines **336**

LUDWIG A. LETTAU, MD, MPH; DAWN W. BLACKHURST, MS; CONNIE STEED, RN, CIC

Nosocomial Human Parvovirus B19 Infection: Lack of Transmission From a Chronically Infected Patient to Hospital Staff **343**

DELORIS E. KOZIOL, PHD; GARY KURTZMAN, MD; JAMSHED AYUB, PHD;
NEAL S. YOUNG, MD; DAVID K. HENDERSON, MD

Impact of a Shielded Safety Syringe on Needlestick Injuries Among Healthcare Workers **349**

BARBARA YOUNGER, RN, BSN, CIC; ELLA H. HUNT RN; CECIL ROBINSON, RN;
CHERYL MCLEMORE, RN

SHEA POSITION PAPER

SHEA's Initiative for Confronting the Cost-Quality Conundrum **354**

R. MICHAEL MASSANARI, MD, MS; BRYAN SIMMONS, MD;
THE SOCIETY FOR HOSPITAL EPIDEMIOLOGY OF AMERICA

CLINICAL PHARMACOLOGY OF ANTIBIOTICS

Azithromycin and Clarithromycin: Overview and Comparison With Erythromycin **357**

MARC S. WHITMAN, MD; ALLAN R. TUNKEL, MD, PHD

DEPARTMENTS

Republication and Copyright Policy **318**

Information for Authors **320**

Letters to the Editor **324**

SHEA News **369**

Medical News **372**

Media Reviews **374**

Classified Marketplace **376**

THE PUBLICATION OF ADVERTISING IN THE JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE SOCIETY FOR HOSPITAL EPIDEMIOLOGY OF AMERICA OR SLACK INCORPORATED OF THE ADVERTISED PRODUCT OR SERVICE OR OF CLAIMS MADE BY THE ADVERTISER. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT THE POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE SOCIETY.

PUBLISHER: Infection Control and Hospital Epidemiology (ISSN-0899-823X, Canadian GST#129780466) is published exclusively by SLACK Incorporated 12 times a year. Address: 6900 Grove Rd., Thorofare, NJ 08086. Telephone: (609) 848-1000.

COPYRIGHT 1992 by The Society for Hospital Epidemiology of America, Inc. and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

SUBSCRIPTIONS: Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year-\$80.00; Two years-\$115.00; Three years-\$145.00, Institutional: One year-\$90.00; Two years-\$130.00; Three years-\$170.00. Fellows: \$40 per year. Canada: \$18.00 additional each year plus 7% for Canadian Goods & Services tax; all other countries: \$36.00 additional each year. Single copies of current issues may be obtained for \$15.00, United States and possessions; \$20.00 all other countries.

REPRINTS: All requests to reprint or use material published herein should be addressed to Lester J. Robeson, SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086. For reprint orders and prices, contact Lester T. Robeson at (609) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy, plus \$.15 per page is paid directly to Copyright Clearance Center, 27 Congress St., Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

CHANCE OF ADDRESS: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Second-class postage is paid at Thorofare, New Jersey 08086, and additional entry points. **POSTMASTER:** Send address changes to SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents--Clinical Practice, Hospital Literature Index, Cumulative Index to Nursing & Allied Health Literature, Nursing Abstracts, and Laboratory Performance Information Exchange System.

EDITORIAL OFFICES

Vanderbilt University School of Medicine
 A-1131 Medical Center North
 Nashville, TN 37232-2637
 (615) 343-1095; (615) 343-1882 (FAX)
 Email: iche@mcmail.vanderbilt.edu

EDITOR

Michael D. Decker, MD, MPH

MANAGING EDITOR

Susan Cantrell

STATISTICAL EDITOR

Beverly G. Mellen, PhD

SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

ASSOCIATE EDITORS

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

SECTION EDITORS**Beyond Infection Control:****The New Hospital Epidemiology**

Bryan P. Simmons, MD

Stephen B. Kritchevsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

Disinfection and Sterilization

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

Emerging Infectious Diseases

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

From the Laboratory

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

Information Management

John A. Sellick, DO

Buffalo, New York

The International Perspective

Mary D. Nettleman, MD, MS

Richmond, Virginia

Issues in Surgery

James T. Lee, MD, PhD

St. Paul, Minnesota

Medical News

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

Practical Healthcare Epidemiology

Loreen A. Herwaldt, MD

Iowa City, Iowa

SHEA News

Murray D. Batt, MD

Clarksburg, West Virginia

Statistics for Hospital Epidemiology

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

Topics in Long-Term Care

Philip W. Smith, MD

Omaha, Nebraska

Topics in Occupational Medicine

David Weber, MD, MPH

Chapel Hill, North Carolina

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY[®]

EDITORIAL ADVISORY BOARD

- Jacques F. Acar, MD Paris, France
 J. Wesley Alexander, MD Cincinnati, Ohio
 Paul Arnow, MD Chicago, Illinois
 Graham A.J. Ayliffe, MD Birmingham, United Kingdom
 Neil L. Barg, MD Yakima, Washington
 Elizabeth Ann Bolyard, RN, MPH, CIC Atlanta, Georgia
 John M. Boyce, MD Providence, Rhode Island
 Professor Dr. Ilja Braveny Munich, Federal Republic of Germany
 Charles Bryan, MD Columbia, South Carolina
 Christian Brun-Buisson, MD Creteil, France
 Donald E. Craven, MD Boston, Massachusetts
 Sue Crow, MSN, RN, CIC Shreveport, Louisiana
 Franz Daschner, MD Freiburg, Federal Republic of Germany
 Leigh G. Donowitz, MD Charlottesville, Virginia
 Charles E. Edmiston, Jr., PhD Milwaukee, Wisconsin
 Theodore C. Eickhoff, MD Denver, Colorado
 Bruce Farber, MD Manhasset, New York
 Victoria J. Fraser, MD St. Louis, Missouri
 Peter C. Fuchs, MD, PhD Black Butte, Oregon
 Richard A. Garibaldi, MD Farmington, Connecticut
 Velvl Greene, PhD, MPH Beer Sheva, Israel
 Robert Gaynes, MD Atlanta, Georgia
 David W. Gregory, MD Nashville, Tennessee
 David K. Henderson, MD Bethesda, Maryland
 Peter N.R. Heseltine, MD Los Angeles, California
 Karen Hoffmann, RN, CIC, MS Chapel Hill, North Carolina
 Marguerite McMillan Jackson, RN, PhD San Diego, California
 Janine Jagger, MPH, PhD Charlottesville, Virginia
 William R. Jarvis, MD Atlanta, Georgia
 Douglas S. Kernodle, MD Nashville, Tennessee
 Robert H. Latham, MD Nashville, Tennessee
 Lewis B. Lefkowitz, MD Nashville, Tennessee
 Hsieh-Shong Leu, MD, MSc Taipei, Taiwan
 Jack Levy, MD Brussels, Belgium
 Victor Lorian, MD Bronx, New York
 Dennis G. Maki, MD Madison, Wisconsin
 Professor Dr. Walter Marget Munich, Federal Republic of Germany
 William J. Martone, MD Bethesda, Maryland
 Allison McGeer, MD Toronto, Ontario, Canada
 John E. McGowan, Jr., MD Atlanta, Georgia
 Jonathan L. Meakins, MD, DSc Montreal, Quebec, Canada
 Raf Mertens, MD Brussels, Belgium
 Robert R. Muder, MD Pittsburgh, Pennsylvania
 Joseph M. Mylotte, MD, CIC Buffalo, New York
 Lindsay Nicolle, MD Winnipeg, Manitoba, Canada
 Juhani Ojajarvi, MD Helsinki, Finland
 Michael T. Osterholm, PhD, MPH Minneapolis, Minnesota
 Jan Evans Patterson, MD San Antonio, Texas
 Sindy M. Paul, MD Trenton, New Jersey
 Michael A. Pfaller, MD Iowa City, Iowa
 Samuel Ponce de Leon, MD, MSc Mexico City, Mexico
 Isaam Raad, MD Houston, Texas
 Manfred L. Rotter, MD, DipBact Vienna, Austria
 Theodore Sacks, MD Jerusalem, Israel
 William E. Scheckler, MD Madison, Wisconsin
 Kent Sepkowitz, MD New York City, New York
 Denis Spelman, MD Prahran Victoria, Australia
 Michael L. Tapper, MD New York, New York
 Clyde Thornsberrry, PhD Brentwood, Tennessee
 Professor Leonid P. Titov Minsk, Republic of Belarus
 Timothy R. Townsend, MD Millwood, Virginia
 Antoni Trilla, MD, PhD Barcelona, Spain
 Professor Wang Shu-Qun Beijing, People's Republic of China
 J. John Weems, Jr., MD Greenville, South Carolina
 Robert A. Weinstein, MD Chicago, Illinois
 Professor Dr. W. Weuffen Greifswald, Federal Republic of Germany
 Sergio B. Wey, MD São Paulo, Brazil
 Rebecca Wurtz, MD Evanston, Illinois

SLACK Incorporated

6900 Grove Road
 Thorofare, New Jersey 08086
 (609) 848-1000

Vice President/Group Publisher

Richard N. Roash

Publisher

John C. Carter

Editorial Director

Jennifer Kilpatrick

Production Editor

Shirley P. Strunk, ELS

Assistant Editor

Eileen C. Anderer

Circulation Manager

Lester J. Robeson, CCCC

Production Director

Christine Malin

Production Coordinator

Joanne Patterson

Publishing Director/ Advertising

Wayne McCourt

Pharmaceutical Group Sales Director

Michael LoPresti

Advertising Sales Representative

Jennine Kane

Classified/Recruitment Sales Manager

Michele Burch

What do you mean I'm *not* protected?

If you are in the habit of applying hand cream after using a Chlorhexidine Gluconate (CHG) handwash, you may actually be losing your protection! A recent study* confirms that residual CHG can be neutralized by anionic hand creams.

Introducing...**Lotion Soft@ Skin Conditioner**, a nonionic skin care lotion compatible with any CHG handwashing product. **Lotion Soft@ Skin Conditioner** contains emollients and moisturizers, which are soothing and last through several handwashes.

When you scrub with CHG for antimicrobial protection, you should be using a compatible product for skin conditioning. Try new **Lotion Soft@ Skin Conditioner**. It will not interfere with the cumulative effects of CHG.

Contact your local Calgon Vestal Healthcare Market Specialist or call toll-free 1-800-325-8005 to find out about new CHG compatible **Lotion Soft@ Skin Conditioner**.

Lotion Soft Skin Conditioner
The compatible companion



**CALGON
VESTAL**
LABORATORIES

DIVISION OF CALGON CORPORATION
SUBSIDIARY OF **MERCK**
& CO., INC.

Box 147, ST. LOUIS, MO 63166

1-800-325-8005

**test data on file*

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY™

The Society for Hospital Epidemiology of America (SHEA) and SLACK Inc. Copyright and Republication Policy

The Society for Hospital Epidemiology of America (SHEA) and SLACK Inc. hold copyright on *Infection Control and Hospital Epidemiology*. We request that all authors of works transfer to SHEA and SLACK Inc. all rights, title, and interest to such works, including copyright. In accord with the Copyright Act of 1976, we must acquire every author's signature to effect the transfer. A written work cannot be considered for publication until the 'Assignment of Copyright' form is signed by the author or authors and is on file at the editorial offices. Please submit this signed form with your manuscript. In the event that a manuscript is not accepted for publication, this agreement will be returned to the authors.

Signed 'Assignment of Copyright' forms confirm that a work submitted has not previously been published, is not subject to copyright or other rights except those of the author to be transferred to SHEA and SLACK Inc., and is not under consideration for publication elsewhere, except under circumstances communicated to us in writing at the time the work is submitted.

Permission to reproduce any part of the works published by SHEA and SLACK Inc. in *Infection Control and Hospital Epidemiology* in any form or by any means, electronic or mechanical, is not permitted without written permission from SLACK Inc.

Assignment of Copyright

In consideration of SLACK Incorporated and The Society for Hospital Epidemiology of America (collectively called the 'Publisher') in publishing my (our) submitted manuscript, the undersigned hereby transfer(s), assign(s), and otherwise convey(s) all copyright in the manuscript to the Publisher. The undersigned declares that the manuscript is original and, to the best of the undersigned's knowledge, contains no matter that is libelous or unlawful or that infringed upon anyone else's rights of copyright.

In addition, we affirm that the work is the work of every author listed, and is not under consideration for publication elsewhere, except under circumstances communicated to us in writing at the time the work is submitted.

MANUSCRIPT NUMBER (if known) _____ DATE _____

AUTHORS _____

TITLE _____

ALL AUTHORS

Signature _____ Date _____

Signature _____ Date _____

Signature _____ Date _____

Signature _____ Date _____

Signature _____ Date _____

Signature _____ Date _____

Signature _____ Date _____

This form may be photocopied.

Techni-CareTM Surgical Scrub

99.99% Bacterial Reduction
in only 30 seconds

Techni-Care...A new technology in a surgical scrub exhibits outstanding antimicrobial efficacy *without* dermal irritation.



Fully substantiated by independent testing in vivo and in vitro, Techni-Care Surgical Scrub both disinfects and conditions *in less time than any prior technology available to healthcare personnel.*

Results of Time Kill tests demonstrate that Techni-Care eliminates gram negative and gram positive bacteria at 99.99% in 30 second contact.

Outstanding Bactericidal Activity without skin irritation

Techni-Care's active ingredient, chloroxylenol (PCMX) at 3%, eliminates bacteria, while a host of skin conditioning agents work synergistically to condition and soften the skin. Exceptionally mild, Techni-Care's dermal conditioning ingredients, include cocamidopropyl PG-Dimonium Chloride Phosphate, Aloe Vera Gel, Collagen and Propylene Glycol.

Techni-Care has rated a "minimal irritation" in the Draize Dermal irritation test. Specially blended formulation for dermal conditioning, as well as for bacterial reduction. Techni-Care Surgical Scrub is soothing to dermal tissue while phospholipids promote natural turgor.



CARE-TECH[®] LABORATORIES

Advanced Skin Care Technology

1-800-325-9681